Organization | Cellonis Biotechnology Co. Ltd.

Cellonis Biotechnology Co. Ltd. Report issue

For profit Phase 1 Phase 2

Founded: Beijing China (2004)

Organization Overview

First Clinical Trial

2010

NCT01142050

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (2)

allogeneic adipose derived mesenchymal stem cell (2 trials)

autologous endothelial progenitor cells (1 trial)

Drugs in Phase 1 Trials (2)

autologous human cord blood derived stem cells (1 trial)

autologous mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Infarction (Phase 2)

Infarction, Middle Cerebral Artery (Phase 2)

Stroke (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 4